Pulse Biosciences

Pulse Biosciences, Inc. operates as an immuno-oncology company developing a proprietary oncolytic electroceutical therapy based on its Nano Pulse Stimulation (NPS) technology. It manufactures surgical and medical instruments uses a novel and proprietary platform technology called Nano-Pulse Electro-Signaling. The NPES provides local tumor control and initiates an adaptive immune response with a vaccine-like effect by inducing immunogenic apoptosis of the cells. The company was founded on May 19, 2014 and is headquartered in Hayward, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pulse Biosciences pivots to cardiac tech, eyes FDA device market

Pulse Biosciences reported financials, highlighted cardiac ablation technology, and pivoted towards an FDA-approved device for cellular repair, showcasing adaptability and strategic focus.
The company faces challenges in transitioning focus areas and managing financial projections but has strengths in innovation, market potential, and strategic autonomy.
Opportunities lie in licensing breakthrough technologies, commercial partnerships, regulatory milestones, and market disruption, positioning Pulse Biosciences for growth and success.
Overall, Pulse Biosciences' strategic shifts, financial prudence, and focus on innovation present a promising outlook for sustainable growth and market expansion.

Pulse Biosciences advances cardiac ablation tech with strong financials

Pulse Biosciences made notable progress in Q1 2023, showcasing financial improvements, key leadership additions, and advancements in developing innovative cardiac ablation technologies.
While facing challenges in clinical validation and regulatory processes, the company's strategic roadmap and focus on nsPFA technology position them well for future growth and success.
With a strong financial position, experienced leadership, and a clear vision for product development, Pulse Biosciences is poised to capitalize on the market opportunities in cardiac ablation.

Pulse Biosciences advances nsPFA technology in cardiac applications, boosts finances

Pulse Biosciences demonstrated strong progress in nsPFA technology for cardiac applications and showcased financial improvements.
While facing questions about study expansions and project exits, the company remains confident in its market position.
Opportunities lie in expanding nsPFA applications, leveraging positive feedback, and exploring strategic partnerships for growth.

Pulse Biosciences advances CellFX technology, reduces costs, eyes growth opportunities

Pulse Biosciences demonstrated strong performance in technology advancement, cost management, and stakeholder engagement, positioning the company for growth.
Despite challenges related to patent concerns, the company's focus on innovation, safety, and partnerships presents opportunities for expansion and market leadership.
With a solid financial position, strategic development goals, and a commitment to excellence, Pulse Biosciences is poised for continued success in the medical technology sector.

Pulse Biosciences advances innovative surgical technology with promising FDA clearances

Pulse Biosciences is optimistic about the future impact of its energy technology on surgery and emphasizes the importance of strong support structures for successful product launches.

Pulse Biosciences excels in Q2, poised for transformative medical advancements

Pulse Biosciences' Q2 2024 performance reflects progress, financial strength, and strategic focus on pivotal clinical trials.
While facing challenges such as increased costs and operational complexities, the company is well-positioned to leverage opportunities in transformative medical technologies.
With a solid financial foundation, strong leadership, and innovative products, Pulse Biosciences is poised for continued growth and market success.
Navigating regulatory hurdles and market competition will be key as the company advances its nano-PFA technology in medical treatments.

Pulse Biosciences reports Q3 loss, strengthens balance sheet for growth

Pulse Biosciences' Q3 2024 earnings call highlighted progress in medical applications, a strengthened balance sheet, and a focus on pivotal clinical studies in 2025.
While facing challenges with increased expenses and net loss, the company's innovative technology and strategic fundraising efforts position it for future growth.
Opportunities lie in advancing clinical studies, expanding product applications, and solidifying its presence in the healthcare market through strategic partnerships.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Pulse Biosciences Inc (PLSE) Q4 2023 Earnings Call Transcript

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced business updates and financial results for the fourth quarter and full year ended December 31, 2023. Recent Business Highlights CellFX nsPFA Percutaneous Electrode (End-effector of the proprietary designed and engineered CellFX nsPFA energy delivery system) Received U.S. FDA 510(k) clearance for us.

Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2023 Financial Results

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced that its Board of Directors has unanimously approved plans to initiate a rights offering. The rights offering of up to $60 million worth of units (“Units”) will be available to all holders of record of the Company's common stock, par value $0.01 (the “Common Stock”) as of the close of the market on.

Pulse Biosciences Announces Plans to Initiate a Rights Offering

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE, “the Company”), a company leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced it will report financial results for the fourth quarter and full year 2023 after market close on Thursday, March 28, 2024. Company management will host a corresponding conference call beginning at 1:30pm PT / 4:30pm ET. Investors interested in listening to the conference call may do s.

Pulse Biosciences Schedules Fourth Quarter & Full Year 2023 Financial Results Conference Call for March 28, 2024

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced receipt of U.S. Food and Drug Administration (FDA) 510(k) clearance for its novel CellFX nsPFA Percutaneous Electrode System for use in the ablation of soft tissue in percutaneous and intraoperative surgical procedures. “The FDA clearance of our Percutaneous Electrode System is the initial major mil.

Pulse Biosciences Announces FDA 510(k) Clearance for its CellFX® nsPFA™ Percutaneous Electrode System

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company with a primary focus on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced favorable findings from the 60-day post-procedure evaluations for four initial patients treated in the Company's CellFX® nsPFA™ 360° Cardiac Catheter First-In-Human Feasibility Study. “The 60-day remap results for the initial patients tr.

Pulse Biosciences Announces Positive 60-Day Follow-Up Evaluations for Initial Patients treated in the CellFX® nsPFA™ 360° Cardiac Catheter First-in-Human Feasibility Study

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company with a primary focus on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field (nsPFA) technology for the treatment of atrial fibrillation, today announced that its nsPFA technology will be featured in a podium presentation at the 29th Annual AF Symposium in Boston, Massachusetts, on February 2, 2024 at 10:00am ET. The session will include a presentation on the latest developments in Nanosecond Puls.

Pulse Biosciences Announces Preliminary Findings from its CellFX nsPFA 360 Cardiac Catheter First-In-Human Feasibility Study to be Featured in Podium Presentation at the AF Symposium

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company primarily focused on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced the filing of a premarket notification 510(k) to the U.S. Food and Drug Administration (FDA) for its novel CellFX nsPFA Cardiac Clamp. Pursuant to Section 510(k), once the application has been accepted, the FDA will conduct its substantive.

Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX® nsPFA™ Cardiac Clamp

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company primarily focused on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced the completion of the first five procedures in its first-in-human feasibility study with its novel CellFX nsPFA cardiac catheter. All patients were successfully discharged by treating physicians. Patients will continue to be monitored and e.

Pulse Biosciences Announces First-in-Human Procedures with its Novel CellFX™ Nanosecond Pulsed Field Ablation (nsPFA™) Cardiac Catheter

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company primarily focused on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced the filing of a premarket notification 510(k) to the U.S. Food and Drug Administration (FDA) for its novel CellFX nsPFA percutaneous electrode. The Company's percutaneous electrode is an image-guided needle designed to harness CellFX nsPFA.

Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX nsPFA Percutaneous Electrode

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company primarily focused on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced plans to present at the upcoming 35th Annual Piper Sandler Healthcare Conference in New York. Management is scheduled to present on Wednesday, November 29, 2023 at 8:10am ET. A live and archived webcast of the presentation will be available.

Pulse Biosciences to Present at the 35th Annual Piper Sandler Healthcare Conference

Pulse Biosciences, Inc. (NASDAQ:PLSE ) Q3 2023 Earnings Conference Call November 13, 2023 12:00 PM ET Company Participants Philip Taylor - IR Kevin Danahy - President and CEO Darrin Uecker - CTO and Director Mitchell Levinson - Chief Strategy Officer Michael Koffler - VP of Finance Bob Duggan - Chairman Conference Call Participants Operator Greetings, and welcome to the Pulse Biosciences Third Quarter 2023 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.

Pulse Biosciences, Inc. (PLSE) Q3 2023 Earnings Call Transcript

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company primarily focused on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced financial results for the third quarter ended September 30, 2023. Recent Business Highlights Advanced feasibility and preclinical studies for the cardiac ablation clamp and catheter programs, and expect to file an FDA 510(k) submission for.

Pulse Biosciences Reports Business Updates and Third Quarter 2023 Financial Results

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE, “the Company”), a company primarily focused on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced it will now report financial results for the third quarter of 2023 before market opens on Monday, November 13, 2023. Company management will now host a corresponding conference call beginning at 9:00am PT / 12:00pm ET. Invest.

UPDATE Pulse Biosciences Announces New Time for Third Quarter 2023 Financial Results Conference Call

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE, “the Company”), a company primarily focused on leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced it will report financial results for the third quarter of 2023 after market close on Monday, November 13, 2023. Company management will host a corresponding conference call beginning at 1:30pm PT / 4:30pm ET. Investors interested in.

Pulse Biosciences Schedules Third Quarter 2023 Financial Results Conference Call for November 13, 2023

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE, “the Company”), a company primarily focused on leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced the appointment of Niv Ad, M.D. as Chief Science Officer, Cardiac Surgery. “After working with the Pulse Biosciences' team and participating in preclinical studies using the nsPFA clamp for cardiac ablation, it was immediately clear.

Pulse Biosciences Appoints Dr. Niv Ad as Chief Science Officer, Cardiac Surgery

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE, “the Company”), a company primarily focused on leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced a collaboration with CardioNXT, to support Pulse Biosciences' planned nsPFA cardiac catheter first-in-human study focused on the treatment of atrial fibrillation. “We are excited to announce this collaboration and the progress we've.

Pulse Biosciences Announces Collaboration with CardioNXT for nsPFA First-in-Human Atrial Fibrillation Study

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE, “the Company”), a company primarily focused on leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced its nsPFA technology will be featured in a presentation at the Global EP Summit 2023 in Cleveland, OH from September 29th to 30th, 2023. “I believe Pulse Biosciences' nsPFA circumferential catheter system represents a novel and high.

Pulse Biosciences' Nanosecond Pulsed Field Ablation (nsPFA™) Circumferential Catheter System to be Featured in a Presentation at the Global EP Summit

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE, “the Company”), a company primarily focused on leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced its nsPFA technology will be featured in two poster presentations at the upcoming American Thyroid Association 2023 Annual Meeting in Washington D.C. from September 27th to October 1st, 2023. “I am proud to have been a part of the f.

Pulse Biosciences' First Study in a Surgical Application of Nanosecond Pulsed Field Ablation (nsPFA) Technology to be Featured in Two Poster Presentations at the American Thyroid Association Annual Meeting

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE, “the Company”), a company primarily focused on leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced plans to participate at the upcoming Gilmartin Group Emerging Growth Showcase, taking place virtually. Members of management are scheduled to present on Thursday, September 21, 2023 at 10:30am PT. A live and archived webcast of the.

Pulse Biosciences to Present at Gilmartin Group Emerging Growth Showcase

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE, “the Company”), a company primarily focused on leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today provided additional clarification regarding the details of the SEC form S-3 (“the filing”) filed August 11, 2023. The only shares registered in the filing are those currently owned by the “selling securityholder”, identified as Robert W. Dugg.

Pulse Biosciences Clarifies Details of Recent S-3 Filing

Pulse Biosciences Inc. (NASDAQ:PLSE ) Q2 2023 Results Conference Call August 10, 2023 4:30 PM ET Company Participants Philip Taylor - IR Kevin Danahy - Chief Executive Officer Darrin Uecker - CTO & Director Mitchell Levinson - Chief Strategy Officer Michael Koffler - Director of Finance Bob Duggan - Chariman of the Board of Pulse Biosciences Operator Greetings, and welcome to Pulse Biosciences' Second Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode.

Pulse Biosciences Inc. (PLSE) Q2 2023 Earnings Call Transcript

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company primarily focused on leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced financial results for the second quarter ended June 30, 2023. Business Updates Demonstrated that an nsPFA cardiac clamp can consistently perform transmural ablations in cardiac muscle up to approximately 25 millimeters thick in 1.25 seconds in pre.

Pulse Biosciences Reports Business Updates and Second Quarter 2023 Financial Results

American Assets

Akoya Biosciences Inc

American Vanguard

Cannae Hlds

Domo

Enviva Partners

National Vision Hlds

Globalstar

Heartland Express

I3 Verticals

MillerKnoll

PacWest Bancorp

Pebblebrook Hotel Trust

B. Riley Financial

Skillz

ACELYRIN Inc

SPDR S&P 500 ETF Trust

Stellar Bancorp Inc

StepStone Group

Washington Federal

Zumiez

After covering second-quarter corporate insider activity among mid-cap and large-caps, today's article will cover on the most interesting insider purchases for small-cap companies. Corporate insiders at American Assets Trust, National Vision, Skillz, Enviva, Heartland Express, and Zumiez have been buying significant amounts of shares, signaling confidence in their respective companies. Other notable insider activity among small-cap stocks includes B. Riley Financial, Cannae Holdings, i3 Verticals, whose CEOs have bought million worth of stock in the second quarter.

Strong Small-Cap Insider Buys: Q2 2023

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, announced today it will report financial results for the second quarter of 2023 after market close on Thursday, August 10, 2023. Company management will host a corresponding conference call beginning at 1:30pm PT / 4:30pm ET. Investors interested in listening to the conference call m.

News for Pulse Biosciences Stock (PLSE)